- Home
- XXII vs TIVC Comparison
XXII vs TIVC Comparison
Compare XXII & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XXII | TIVC |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.6M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XXII | TIVC |
|---|---|---|
| Price | $0.56 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 123.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.96 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,832,530.00 | $780,000.00 |
| Revenue This Year | $370.28 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $0.75 |
| 52 Week High | $11.37 | $5.60 |
Technical Indicators
Market Signals| Indicator | XXII | TIVC |
|---|---|---|
| Relative Strength Index (RSI) | 16.90 | 69.31 |
| Support Level | N/A | $0.79 |
| Resistance Level | $1.10 | $2.70 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 2.44 | 100.00 |
Price Performance
Historical ComparisonAbout XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About TIVC Tivic Health Systems Inc.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.